Manuscript Detail

Title: Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics study.

Authors: Hu, Z et al

Abstract: Support for the study was provided from National Institute of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID) (U01 AI150741-01S1 and T32-AI052073), the Stanford's Innovative Medicines Accelerator, National Institutes of Health/National Institute on Drug Abuse (NIH/NIDA) DP1DA046089, and anonymous donors to Stanford University. Peginterferon lambda provided by Eiger BioPharmaceuticals.

Journal: eLife

Author-provided data:

Volunteer to curate Volunteer to review